Induction of p53 protein expression by sodium arsenite

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 381, Issue 2, 1997, Pages 259-265

  Salazar, A M ^a   Ostrosky Wegman, P ^a   Menendez D ^a   Miranda, E ^b   Garcia Carranca A ^a   Rojas, E ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Arsenic; DNA damage; Immunoblot; p53

Indexed keywords

ARSENITE SODIUM; CARCINOGEN; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ARSENITES; CARCINOGENS; CARCINOMA; CELL DIVISION; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; GENES, P53; HELA CELLS; HERPESVIRUS 4, HUMAN; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; SODIUM COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0031589701     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00207-8     Document Type: Article

References (41)

1. [1] IARC (International Agency for Research), Some metals and metallic compounds, in: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Vol. 23, IARC, Lyon, 1980 pp. 39-141.
2. [2] IARC (International Agency for Research), Overall evaluations of carcinogenicity, in: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Suppl. 7, IARC, Lyon, 1987, pp. 100-106.
3. [3] P. Mushak, A.F. Crocetti, Risk and revision in arsenic cancer risk assessment, Environ. Health Perspect. 103 (1995) 684-689.
4. [4] D. Germolec, J. Spalding, G. Boorman, J.L. Wilmer, T. Yoshida, P.P. Simeonova, A. Bruccoleri, F. Kayama, K. Gaido, R. Tennant, F. Burleson, W. Dong, R.W. Lang, M.I. Luster, Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors, Mutation Res. 386 (1997) 209-218.
5. [5] S. Yamamoto, Y. Konishi, T. Matsuda, T. Murai, M.A. Shibata, I. Matsui-Yuasa, S. Otani, K. Kuroda, G. Endo, S. Fukushima, Cancer induction by an organic arsenic compound, dimethylarsenic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens, Cancer Res. 55 (1995) 273-1276.
6. [6] T.G. Rossman, Enhancement of UV-mutagenesis by low concentrations of arsenite in E. coli, Mutation Res. 91 (1981) 207-211.
7. [7] T.C. Lee, R.Y. Haung, K.Y. Jan, Sodium arsenite enhances the cytotoxicity, clastogenicity and 6-thioguanine-resistant mutagenicity of ultraviolet light in Chinese hamster ovary cells, Mutation Res. 148 (1985) 83-89.
8. [8] T.C. Lee, K.C. Lee, Y.J. Tzeng, R.Y. Huang, K.Y. Jan, Sodium arsenite potentiates the clastogenicity and mutagenicity of DNA crosslinking agents, Environ. Mutagen. 8 (1986) 119-128.
9. [9] J.H. Li, T.G. Rossman, Mechanism of comutagenesis of sodium arsenite with N-methyl-N-nitrosourea, Biol. Trace Elem. 21 (1989) 373-381.
10. [10] J.H. Li, T.G. Rossman, Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis, Mol. Toxicol. 2 (1989) 1-9.
11. [11] D. Jacobson-Kram, D. Montalbano, The reproductive effects assessment group's report on the mutagenicity of inorganic arsenic, Environ. Mutagen. 7 (1985) 778-804.
12. [12] T.-C. Lee, N. Tanaka, P.W. Lamb, T.M. Gilmer, J.C. Barrett, Induction of gene amplification by arsenic, Science 241 (1988) 79-81.
13. [13] J.W. Yager, J.K. Wiencke, Inhibition of poly (ADP-ribose) polymerase by arsenite, Mutation Res. 386 (1997) 345-351.
14. [14] M.E. Gonsebatt, R. Montero, L. Vega, H. Barba, J. Espinosa, G. García-Vargas, L. Del Razo, M.E. Cebrián, P. Ostrosky-Wegman, Genotoxic and 'nongenotoxic' effects in arsenic human exposure. International Semin. Proceeding, Arsenic in the Environment and its Incidence on Health, Santiago Chile, 1992, pp. 15-19.
15. [15] L. Vega, M.E. Gonsebatt, P. Ostrosky-Wegman, Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected, Mutation Res. 334 (1995) 365-373.
16. [16] M.E. Gonsebatt, P. Ostrosky-Wegman, L. Vega, A.M. Salazar, R. Montero, P. Guzmán, J. Blas, L.M. Del Razo, G. García-Vargas, A. Albores, M.E. Cebrián, M. Kelsh, Cytogenetic effects in human exposure to arsenic, Mutation Res. 386 (1997) 219-228.
17. [17] P. Ramírez, D.A. Eastmond, J.P. Laclette, P. Ostrosky-Wegman, Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide, Mutation Res. 386 (1997) 291-298.
18. [18] P. Ostrosky-Wegman, M.E. Gonsebatt, R. Montero, L. Vega, H. Barba, J. Espinosa, A. Palao, C. Cortinas, G. García-Vargas, L.M. Del Razo, M. Cebrián, Lymphocyte proliferation kinetics and genotoxic findings in pilot study on individuals chronically exposed to arsenic in Mexico, Mutation Res. 250 (1991) 477-482.
19. [19] M.E. Gonsebatt, L. Vega, L.A. Herrera, R. Montero, E. Rojas, M.E. Cebrián, P. Ostrosky-Wegman, Inorganic arsenic effects on human lymphocyte stimulation and proliferation, Mutation Res. 283 (1992) 91-95.
20. [20] M.E. Gonsebatt, L. Vega, R. Montero, G. García-Vargas, L.M. Del Razo, A. Albores, M.E. Cebrián, P. Ostrosky-Wegman, Lymphocyte replicating ability in individuals exposed to arsenic via drinking water, Mutation Res. 313 (1994) 293-299.
21. [21] M. Cavigelli, W.W. Li, A. Lin, B. Su, K. Yoshioka, M. Karin, The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase, EMBO J. 15 (1996) 6269-6279.
22. [22] C.C. Harris, M. Hollstein, Clinical implications of the p53 tumor suppressor gene, New Engl. J. Med. 329 (1993) 1318-1327.
23. [23] A.J. Levine, The tumor suppressor genes, Annu. Rev. Biochem. 62 (1993) 623-651.
24. [24] R.A. Weinberg, Tumor suppressor genes, Science 245 (1991) 1138-1146.
25. [25] C.C. Harris, The p53 tumor suppressor gene: at crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment, Science 262 (1993) 1980-1981.
26. [26] M.S. Greenblatt, W.P. Bennett, M. Hollstein, C.C. Harris, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res. 53 (1994) 5377-5381.
27. [27] C.H. Blattener, A. Knebel, A. Radler-Pohl, C.H. Sachsenmaier, P. Herrlich, J. Rahmsdorf, DNA damaging agents and growth factors induce changes in the program of expressed gene products through common routes, Environ. Mol. Mutagen. 24 (1994) 3-10.
28. [28] S.M. Cross, C.A. Sanchez, C.A. Morgan, M.K. Schimke, S. Ramel, R.L. Idzerda, W.H. Raskind, B.J. Reid, A p53-dependent mouse spindle checkpoint, Science 267 (1995) 1353-1356.
29. [29] R. Haffner, M. Oren, Biochemical properties and biological effects of p53, Curr. Opin. Gen. Dev. 5 (1995) 84-90.
30. [30] M.J. Mass, L. Wang, Arsenic alters cytosine methylation patterns of the tumor suppressor gene p53 promoter in human lung cells: a model for a mechanism of carcinogenesis, Mutation Res. 386 (1997) 263-277.
31. [31] G.L. Andreason, G.A. Evans, Introduction and expression of DNA molecules in eukarytic cells by electroporation, BioTech. 6 (1988) 650-670.
32. [32] F. Toneguzzo, A.C. Hayday, A. Keating, Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells, Mol. Cell. Biol. 6 (1986) 703-706.
33. [33] M. Guido, R. Zamorano, E. Garrido-Guerrero, P. Gariglio, A. García-Carrancá, Early promoters of genital and cutaneous human papilloma viruses are differentially regulated by the bovine papilloma virus type 1E2 gene product, J. Gen. Virol. 73 (1992) 1395-1400.
34. [34] J.E. Dinchuk, K.A. Kelley, G.N. Callahan, Flow cytometric analysis of transport activity in lymphocytes electroporated with a fluorescent organic anion dye, J. Immunol. Methods 155 (1992) 257-265.
35. [35] M. Scheffner, K. Münger, J.C. Byrne, P.M. Howley, The state of p53 and retinoblastoma genes in human cervical carcinoma cell lines, Proc. Natl. Acad. Sci. USA 88 (1991) 5523-5527.
36. [36] A. Schneider-Gädicke, E. Schwarz, Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes, EMBO J. 5 (1986) 2285-2292.
37. [37] M.J. Allday, A. Sinclair, G. Parker, D.H. Crawford, P.J. Farrell, Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53, EMBO J. 14 (1995) 1382-1391.
38. [38] J. Cheng, M. Haas, Frequent mutations in p53 tumor suppressor gene in human leukemia T-cell lines, Mol. Cell. Biol. 10 (1990) 5502-5509.
39. [39] S. Hassapoglidou, E.P. Diamandis, D.J.A. Sutherland, Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry, Oncogene 8 (1993) 1501-1509.
40. Val-138: Modulation of the cell cycle, viability and expression of p53-responsive genes, Oncogene 11 (1995) 1-6.
41. [41] J. Milner, The role of p53 in normal control of cell proliferation, Curr. Opin. Cell Biol. 3 (1991) 282-286.